Umirolimus - Biosensors International

Drug Profile

Umirolimus - Biosensors International

Alternative Names: A9; AXXESS; Ba9; BioFreedom; Biolimus A9 (BA9); Biolimus A9-drug-eluting stent; Biolimus-A9; BioMatrix; BioMatrix Flex; BioMatrix NeoFlex; BMX-J; Custom NX; Nobori; TRM-986

Latest Information Update: 07 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biosensors International Pte Ltd
  • Developer Biosensors International Group; Terumo
  • Class Macrolides
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis

Most Recent Events

  • 08 Nov 2017 Phase-II clinical trials in Coronary artery restenosis in Switzerland (Intracoronary) (NCT03118895)
  • 11 Sep 2017 Phase-III development for Coronary artery restenosis is ongoing in Canada (Intracoronary) (NCT02843633)
  • 21 Apr 2017 Biosensors Europe plans a clinical trial for Coronary artery restenosis in Switzerland and United Kingdom (Intracoronary) (NCT03118895)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top